{"entity":{"id":"nct07245446","kind":"trial","name":"A Study of Ivonescimab in First-Line ES-SCLC","aka":[],"tldr":"A phase 2 trial of Ivonescimab, Cadonilimab, AK117 in small-cell lung cancer, run by Akeso, now recruiting.","summary":"A Study of Ivonescimab in First-Line ES-SCLC is a phase 2 interventional study registered as NCT07245446 by Akeso, with 180 participants planned, started 2025-10-29 and due to reach its primary completion in 2027-12. Interventions recorded: Ivonescimab, Cadonilimab, AK117, Etoposide, Carboplatin (AUC 5). Conditions listed: Extensive-stage Small Cell Lung Cancer (ES-SCLC). No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07245446","url":"https://clinicaltrials.gov/study/NCT07245446"}],"tags":["ctgov-ingest"],"related":[],"cancers":["sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["ivonescimab","cadonilimab","ak117","etoposide","carboplatin"],"companies":["akeso"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07245446","phase":"2","setting":"A Phase II Clinical Study of Ivonescimab Combination Therapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)","sponsor":"Akeso","enrolled":180,"outcomes":[]},"route":"/trials/nct07245446/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"ak117","kind":"drug","name":"AK117","route":"/drugs/ak117/"},{"id":"cadonilimab","kind":"drug","name":"Cadonilimab","route":"/drugs/cadonilimab/"},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"etoposide","kind":"drug","name":"Etoposide","route":"/drugs/etoposide/"},{"id":"ivonescimab","kind":"drug","name":"Ivonescimab","route":"/drugs/ivonescimab/"}],"company":[{"id":"akeso","kind":"company","name":"Akeso","route":"/companies/akeso/"}]}}